Oct 11 (Reuters) - Aerie Pharmaceuticals Inc's experimental glaucoma treatment Rhopressa is effective in lowering eye pressure, a preliminary review by the U.S. Food and Drug Administration concluded.
The review, posted on Wednesday on the FDA's website, comes two days ahead of a meeting of outside experts who will advise the agency on whether the treatment should be approved.
Glaucoma, a condition caused by damage to the optic nerve, is the second-leading cause of blindness in the world. It is expected to affect more than 4 million Americans by 2030, up from 2.7 million today.
*****
Description
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
Key stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -41.29% | -48.63% |
| Return on average equity | -84.74% | -159.62% |
| Employees | 95 |
No comments:
Post a Comment